USANA Health Sciences (USNA) Misses Q4 EPS by 25c

USANA Health Sciences (NYSE: USNA) reported Q4 EPS of $1.03, $0.25 worse than the analyst estimate of $1.28. Revenue for the quarter came in at $267 million versus the consensus estimate of $271.93 million.

GUIDANCE:

USANA Health Sciences sees FY2022 EPS of $5.25-$6.00, versus the consensus of $5.78. USANA Health Sciences sees FY2022 revenue of $1.125-1.225 billion, versus the consensus of $1.17 billion.

For earnings history and earnings-related data on USANA Health Sciences (USNA) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• USANA Introduces 3-in-1 Protein, Creatine, and Electrolyte Drink Mix
• XP Inc. (XP) Tops Q2 EPS by 8c